Paper23940286
Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.
Ajona D and 13 others. J Natl Cancer Inst, 2013. Cited by 138 papers, by iCite.
Cite this record
ConductScience Library. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. Papers, record 23940286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23940286
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Bronchoalveolar Lavage Fluid | Major topic |
| Complement C4b | Major topic |
| Lung Neoplasms | Major topic |
| Peptide Fragments | Major topic |
| Adult | |
| Aged | |
| Complement Activation | |
| Complement Pathway, Classical | |
| Early Detection of Cancer | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Predictive Value of Tests | |
| Prognosis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| U01 CA152662 | NCI NIH HHS | United States | U01CA152662 | PubMed and NIH |
Source NIH RePORTER
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1323139 | Immunoglobulins and complement components levels in patients with lung cancer. | Rom J Intern Med | 1992 | https://conductscience.org/library/papers/1323139 | PubMed |
| 2 | 17442984 | Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. | J Immunol | 2007 | https://conductscience.org/library/papers/17442984 | PubMed |
| 3 | 18250442 | C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. | J Immunol | 2008 | https://conductscience.org/library/papers/18250442 | PubMed |
| 4 | 977762 | Immunoglobulins and complement in pleural effusions associated with bronchogenic carcinoma. | J Clin Pathol | 1976 | https://conductscience.org/library/papers/977762 | PubMed |
| 5 | 21481963 | Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. | Lung Cancer | 2011 | https://conductscience.org/library/papers/21481963 | PubMed |
| 6 | 21300873 | MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/21300873 | PubMed |
| 7 | 16489012 | Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. | Cancer Res | 2006 | https://conductscience.org/library/papers/16489012 | PubMed |
| 8 | 7545058 | Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. | Am J Respir Crit Care Med | 1995 | https://conductscience.org/library/papers/7545058 | PubMed |
| 9 | 16177255 | Immune response as a biomarker for cancer detection and a lot more. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16177255 | PubMed |
| 10 | 23226093 | Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. | Neoplasia | 2012 | https://conductscience.org/library/papers/23226093 | PubMed |
| 11 | 20720586 | Complement: a key system for immune surveillance and homeostasis. | Nat Immunol | 2010 | https://conductscience.org/library/papers/20720586 | PubMed |
| 12 | 17548110 | Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. | Mol Immunol | 2008 | https://conductscience.org/library/papers/17548110 | PubMed |
| 13 | 21714641 | Reduced lung-cancer mortality with low-dose computed tomographic screening. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21714641 | PubMed |
| 14 | 16395409 | Differential exoprotease activities confer tumor-specific serum peptidome patterns. | J Clin Invest | 2006 | https://conductscience.org/library/papers/16395409 | PubMed |
| 15 | 23028051 | Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. | J Immunol | 2012 | https://conductscience.org/library/papers/23028051 | PubMed |
| 16 | 15342420 | Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. | Cancer Res | 2004 | https://conductscience.org/library/papers/15342420 | PubMed |
| 17 | 9717965 | Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. | Clin Exp Immunol | 1998 | https://conductscience.org/library/papers/9717965 | PubMed |
| 18 | 22689914 | The state of molecular biomarkers for the early detection of lung cancer. | Cancer Prev Res (Phila) | 2012 | https://conductscience.org/library/papers/22689914 | PubMed |
| 19 | 20802023 | Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer. | Cancer Epidemiol Biomarkers Prev | 2010 | https://conductscience.org/library/papers/20802023 | PubMed |
| 20 | 11739526 | Specific inhibition of the classical complement pathway by C1q-binding peptides. | J Immunol | 2001 | https://conductscience.org/library/papers/11739526 | PubMed |
Cited by84
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42472420 | Proteomic characterization of airway obstruction-associated proteins in non-smoking lung adenocarcinoma. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42472420 | PubMed |
| 42238034 | Identification of High-Performing Blood Metabolite Biomarkers of Lung Cancer in a Chinese Population. | Phenomics | 2026 | https://conductscience.org/library/papers/42238034 | PubMed |
| 42129855 | Circulating extracellular vesicles from early-stage lung cancer patients trigger endothelial activation to drive pre-metastatic niche formation through synergistic miR-29a and C4A signaling. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42129855 | PubMed |
| 41819546 | Complement system in cancer: friend or foe of immunotherapy. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41819546 | PubMed |
| 41526546 | The contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia and acute myelogenous leukemia. | Sci Rep | 2026 | https://conductscience.org/library/papers/41526546 | PubMed |
| 41241678 | Complement system in tumor growth and metastases. | Br J Cancer | 2026 | https://conductscience.org/library/papers/41241678 | PubMed |
| 40950900 | Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet? | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40950900 | PubMed |
| 40777024 | Identification of a coagulation-related classification and signature that predict disease heterogeneity for colorectal cancer and pan-cancer patients. | Front Immunol | 2025 | https://conductscience.org/library/papers/40777024 | PubMed |
| 40698088 | Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors-a network meta-analysis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40698088 | PubMed |
| 40622549 | Role of Innate Immunity in Cancer. | Adv Exp Med Biol | 2025 | https://conductscience.org/library/papers/40622549 | PubMed |
| 40612949 | Impact of smoking on the complement system: a narrative review. | Front Immunol | 2025 | https://conductscience.org/library/papers/40612949 | PubMed |
| 40492591 | O-GalNAc Glycosylation Activates MBL-Mediated Complement and Coagulation Cascades to Drive Organotropic Metastasis. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40492591 | PubMed |
| 40210889 | Genetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis. | Sci Rep | 2025 | https://conductscience.org/library/papers/40210889 | PubMed |
| 39764857 | Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer. | Gynecol Oncol | 2025 | https://conductscience.org/library/papers/39764857 | PubMed |
| 39239051 | Complement protein expression changes in various conditions of breast cancer: in-silico analyses-experimental research. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/39239051 | PubMed |
| 39036305 | Activation of the complement system sensitizes immune checkpoint blockade. | J Natl Cancer Cent | 2023 | https://conductscience.org/library/papers/39036305 | PubMed |
| 38881920 | Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/38881920 | PubMed |
| 38375474 | Tea intake and lung diseases: a Mendelian randomization study. | Front Immunol | 2024 | https://conductscience.org/library/papers/38375474 | PubMed |
| 38025810 | Biomarkers of lung cancer for screening and in never-smokers-a narrative review. | Transl Lung Cancer Res | 2023 | https://conductscience.org/library/papers/38025810 | PubMed |
| 37396553 | Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. | Genes Dis | 2023 | https://conductscience.org/library/papers/37396553 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C1QA | 712 | PubTator's text mining | https://conductscience.org/library/genes/712 | NCBI Gene |
| C4B | 721 | PubTator's text mining | https://conductscience.org/library/genes/721 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23940286
GET https://conductscience.org/api/papers/v1/23940286/references?page=2